TTC Survey Assesses Latin American Physicians’ Attitudes toward Clinical Trials

Investigators from Latin America and US Rank Medical Innovation as a Primary Factor for Participating in Clinical Trials

PHILADELPHIA--(BUSINESS WIRE)-- Latin America represents a highly attractive growth market for pharmaceutical products. With an expanding population in the hundreds of millions, the demand for prescription drugs in Latin American will increase, making the need to conduct clinical trials there essential for global pharmaceutical companies. Knowing what motivates Latin American investigators will help companies develop their clinical trial strategies and tactics.

For this survey, TTC polled Latin American physicians and sites and compared the results with survey results for US investigators. TTC’s research examined why investigators choose to take part in clinical research, and what challenges they saw in conducting studies. TTC drew its data from commercially funded clinical trials in Argentina, Brazil, Chile, Colombia, Ecuador, El Salvador, Guatemala, Honduras, Mexico, Peru, and Venezuela.

Key TTC Survey Findings

Medical Innovation: TTC found that Latin American investigators, and their US counterparts, rate the opportunity to take part in medical innovation as the primary reason for participating in commercially-funded clinical research. In Latin America, financial considerations, while important, are secondary to the opportunity to be part of medical innovation.

Clinical Sites: Compared with the US, most Latin American clinical research takes place in hospitals. Unlike the US, few Latin American investigators work in private practice, and they conduct a far larger percentage of their clinical research at dedicated sites.

Project Sponsorship: When compared with US investigators, Latin American investigators place a high value on sponsorship by a major pharmaceutical company. Half of the study’s Latin American investigators indicated that their level of confidence in other drugs already on the market from the sponsor company was very important, especially if the sponsor company was both large and multinational.

Comparable Areas of Dissatisfaction: TTC’s survey found that Latin American and US investigators concurred on a number of areas in which they found clinical trials troublesome. These areas included such financial related activities as tracking clinical trial costs against the budget, accurately forecasting the study budget, followed by reporting serious adverse events (SAE), and the amount spent on site by the study monitor.

For additional information contact TTC, LLC at 215-243-4103

Harold Glass (TTC Principal):

“Latin America represents for many companies an under used area for conducting clinical research. It is important we understand what motivates Latin American investigators to take part in clinical trials, and what these investigators find most challenging in conducting clinical research.”

About GrantPlan® and TTC, LLC

GrantPlan®, a product of TTC, LLC, is the largest database of current clinical investigator budgets. With five distinctive database products, TTC has the largest current database of investigator site budgets from 60 countries. TTC combines a strong financial base, a global reach, and an experienced team of customer-focused professionals proud to serve the industry in managing costs and expediting clinical trials. GrantPlan® contains extensive cost data at the Procedure, Cost per Visit, and Cost per Patient levels from countries involved in drug testing throughout North America, Europe, Asia and Latin America. For more information please visit www.ttc-llc.com.



CONTACT:

TTC, LLC
Michael Shaub, 215-243-4103

KEYWORDS:   United States  North America  Central America  South America  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Hospitals  Pharmaceutical  Other Health  Research  Science  General Health

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.